<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02361216</url>
  </required_header>
  <id_info>
    <org_study_id>LP0105-1032</org_study_id>
    <nct_id>NCT02361216</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest</brief_title>
  <official_title>Efficacy and Safety of Ingenol Mebutate Gel in Field Treatment of Actinic Keratosis on Full Face, Balding Scalp or Approximately 250 cm2 on the Chest</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for
      actinic keratosis applied to large treatment areas once daily for three consecutive days on
      face, scalp or chest.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">March 2017</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Complete Resolution of Actinic Keratosis (AK)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Complete resolution of actinic keratosis (AKclear100) at Week 8 is defined as 100% reduction from baseline in the number of clinically visible AKs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Partial Clearance at Week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Partial clearance (AKclear75 ) is defined as a reduction in the number of clinically visible AKs in the selected treatment area by at least 75% compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Partial Clearance at Week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Partial clearance (AKclear75) defined as a reduction in the number of clinically visible AKs in the selected treatment area by at least 75% compared to baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Reduction From Baseline in AK Count</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent reduction in AK count in the selected treatment area at Week 8</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">729</enrollment>
  <condition>Actinic Keratosis</condition>
  <arm_group>
    <arm_group_label>Ingenol mebutate gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment once daily for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Treatment once daily for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ingenol Mebutate</intervention_name>
    <arm_group_label>Ingenol mebutate gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle gel</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects with 5 to 20 clinically typical, visible and discrete, actinic keratosis (AKs)
        non-hyperkeratotic and non-hypertrophic AKs within a selected treatment area of sun-damaged
        skin on either:

          -  The full face

          -  The full balding scalp

          -  A contiguous area of approximately 250 cm2 on the chest

        Exclusion Criteria:

          -  Location of the treatment area (full face, full balding scalp or chest) within 5 cm of
             an incompletely healed wound or within 5 cm of a suspected basal cell carcinoma (BCC)
             or squamous cell carcinoma (SCC).

          -  Previously assigned treatment in this clinical trial or previously participated in a
             clinical trial in the LEO clinical programme on ingenol mebutate gel for larger
             treatment areas.

          -  Treatment with ingenol mebutate gel in the selected treatment area within the last 12
             months.

          -  Lesions in the treatment area that have: atypical clinical appearance (e.g. cutaneous
             horn) and/or, recalcitrant disease (e.g., did not respond to cryotherapy on two
             previous occasions).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>C. William Hanke, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laser &amp; Skin Surgery Center of Indiana,</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laser &amp; Skin Surgery Center of Indiana</name>
      <address>
        <city>Carmel</city>
        <state>Indiana</state>
        <zip>46032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2015</study_first_posted>
  <results_first_submitted>June 28, 2018</results_first_submitted>
  <results_first_submitted_qc>October 2, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2018</results_first_posted>
  <disposition_first_submitted>April 11, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>April 11, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 12, 2017</disposition_first_posted>
  <last_update_submitted>October 2, 2018</last_update_submitted>
  <last_update_submitted_qc>October 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were followed for 8 weeks following the first application of investigational medicinal product (IMP) at Day 1 (3-day treatment period including an 8-week follow-up period) and for an additional 12 months following Week 8 (extended 12-month follow-up period).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ingenol Mebutate Gel</title>
          <description>Treatment once daily for 3 days
Ingenol mebutate gel 0.027% or vehicle gel was applied on either the full face, full balding scalp, or within a contiguous area of approximately 250 cm2 on the chest.</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Gel</title>
          <description>Treatment once daily for 3 days
Vehicle: Vehicle gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>3 Day Treatment and 8 Week Follow/up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="552"/>
                <participants group_id="P2" count="177"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="541"/>
                <participants group_id="P2" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unacceptable Local Skin Reaction (LSR)</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial site closed</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>12-month Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="541"/>
                <participants group_id="P2" count="157">1 of the 158 subjects did not receive treatment and was also excluded from the 12-month follow-up.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="489"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="52"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ingenol Mebutate Gel</title>
          <description>Treatment once daily for 3 days
Ingenol Mebutate</description>
        </group>
        <group group_id="B2">
          <title>Vehicle</title>
          <description>Treatment once daily for 3 days
Vehicle: Vehicle gel</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="552"/>
            <count group_id="B2" value="177"/>
            <count group_id="B3" value="729"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" lower_limit="38" upper_limit="91"/>
                    <measurement group_id="B2" value="69" lower_limit="45" upper_limit="91"/>
                    <measurement group_id="B3" value="68" lower_limit="38" upper_limit="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="149"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="403"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="535"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="304"/>
                    <measurement group_id="B2" value="98"/>
                    <measurement group_id="B3" value="402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="188"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Complete Resolution of Actinic Keratosis (AK)</title>
        <description>Complete resolution of actinic keratosis (AKclear100) at Week 8 is defined as 100% reduction from baseline in the number of clinically visible AKs</description>
        <time_frame>8 weeks</time_frame>
        <population>Of the 729 subjects randomised to treatment, 4 did not receive treatment. These 4 subjects (3 subjects in active treatment group and 1 in vehicle group) were excluded from the Full Analysis Set (FAS), which consisted of 725 subjects (549 subjects in active treatment group and 176 in corresponding vehicle group). AKclear100 is based on the FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Ingenol Mebutate Gel</title>
            <description>Treatment once daily for 3 days with ingenol mebutate with 8 week follow-up after initial treatment</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Treatment once daily for 3 days vehicle gel with 8 week follow-up after initial treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Complete Resolution of Actinic Keratosis (AK)</title>
          <description>Complete resolution of actinic keratosis (AKclear100) at Week 8 is defined as 100% reduction from baseline in the number of clinically visible AKs</description>
          <population>Of the 729 subjects randomised to treatment, 4 did not receive treatment. These 4 subjects (3 subjects in active treatment group and 1 in vehicle group) were excluded from the Full Analysis Set (FAS), which consisted of 725 subjects (549 subjects in active treatment group and 176 in corresponding vehicle group). AKclear100 is based on the FAS</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="549"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.4"/>
                    <measurement group_id="O2" value="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AKclear100 at Week 8: full analysis set. The null hypothesis was that there is no difference at Week 8 in AKclear100 rates between ingenol mebutate gel 0.027% and vehicle gel. This hypothesis was tested against the 2-sided alternative of a difference between the 2 treatment groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Ratio of clearance rates</param_type>
            <param_value>6.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.82</ci_lower_limit>
            <ci_upper_limit>14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Partial Clearance at Week 8</title>
        <description>Partial clearance (AKclear75 ) is defined as a reduction in the number of clinically visible AKs in the selected treatment area by at least 75% compared to baseline.</description>
        <time_frame>8 weeks</time_frame>
        <population>AKclear75 at Week 8 is based on the full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Ingenol Mebutate Gel</title>
            <description>Treatment once daily for 3 days with ingenol mebutate with 8 week follow-up after initial treatment</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Treatment once daily for 3 days vehicle gel with 8 week follow-up after initial treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Partial Clearance at Week 8</title>
          <description>Partial clearance (AKclear75 ) is defined as a reduction in the number of clinically visible AKs in the selected treatment area by at least 75% compared to baseline.</description>
          <population>AKclear75 at Week 8 is based on the full analysis set (FAS)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="549"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.4"/>
                    <measurement group_id="O2" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The p-values for secondary endpoints have been corrected by the Holm-Bonferroni method to account for multiplicity. The prespecified multiplicity adjustment by the Holm-Bonferroni method requires the ordering of the p-values for the secondary endpoints by size.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Ratio of clearance rates</param_type>
            <param_value>6.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.16</ci_lower_limit>
            <ci_upper_limit>11.1</ci_upper_limit>
            <estimate_desc>Mantel-Haenszel estimate (0.027% relative to vehicle), adjusted for pooled sites</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Partial Clearance at Week 4</title>
        <description>Partial clearance (AKclear75) defined as a reduction in the number of clinically visible AKs in the selected treatment area by at least 75% compared to baseline.</description>
        <time_frame>4 weeks</time_frame>
        <population>AKclear75 at Week 4 is based on the full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Ingenol Mebutate Gel</title>
            <description>Treatment once daily for 3 days
Ingenol Mebutate</description>
          </group>
          <group group_id="O2">
            <title>Vehicle</title>
            <description>Treatment once daily for 3 days
Vehicle: Vehicle gel</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Partial Clearance at Week 4</title>
          <description>Partial clearance (AKclear75) defined as a reduction in the number of clinically visible AKs in the selected treatment area by at least 75% compared to baseline.</description>
          <population>AKclear75 at Week 4 is based on the full analysis set (FAS)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="549"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8"/>
                    <measurement group_id="O2" value="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The p-values for secondary endpoints have been corrected by the Holm-Bonferroni method to account for multiplicity. The pre-specified multiplicity adjustment by the Holm-Bonferroni method requires the ordering of the p-values for the secondary endpoints by size.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Mantel Haenszel</method>
            <param_type>Ratio of clearance rates</param_type>
            <param_value>6.53</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.04</ci_lower_limit>
            <ci_upper_limit>10.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Reduction From Baseline in AK Count</title>
        <description>Percent reduction in AK count in the selected treatment area at Week 8</description>
        <time_frame>8 weeks</time_frame>
        <population>Percent reduction in AK count is based on the full analysis set (FAS)</population>
        <group_list>
          <group group_id="O1">
            <title>Ingenol Mebutate Gel</title>
            <description>Treatment once daily for 3 days with ingenol mebutate with 8 week follow-up after initial treatment</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Gel</title>
            <description>Treatment once daily for 3 days vehicle gel with 8 week follow-up after initial treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Reduction From Baseline in AK Count</title>
          <description>Percent reduction in AK count in the selected treatment area at Week 8</description>
          <population>Percent reduction in AK count is based on the full analysis set (FAS)</population>
          <units>percentage reduction of AK count</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="549"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7" lower_limit="73.9" upper_limit="77.3"/>
                    <measurement group_id="O2" value="12.7" lower_limit="3.0" upper_limit="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The p-values for secondary endpoints have been corrected by the Holm-Bonferroni method to account for multiplicity. The prespecified multiplicity adjustment by the Holm-Bonferroni method requires the ordering of the p-values for the secondary endpoints by size.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Negative binominal regression with log baseline count as offset variable and treatment group, anatomical location stratum and pooled site as factors.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Ratio of clearance</param_type>
            <param_value>0.28</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.24</ci_lower_limit>
            <ci_upper_limit>0.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>14 Months</time_frame>
      <desc>A total of 729 subjects were randomised to treatment, of whom 4 did not receive treatment with IMP. These 4 subjects (3 subjects from the active treatment group and 1 from the corresponding vehicle group) were excluded from the Full Analysis Set, which consisted of 725 subjects (549 subjects in the active treatment group and 176 in the corresponding vehicle group).
The Safety Analysis Set was the same as the Full Analysis Set.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ingenol Mebutate Gel</title>
          <description>Treatment once daily for 3 days
Ingenol Mebutate</description>
        </group>
        <group group_id="E2">
          <title>Vehicle</title>
          <description>Treatment once daily for 3 days
Vehicle: Vehicle gel</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Sternal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="394" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="350" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Application Site Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="203" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>Application Site Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
              <event>
                <sub_title>application site parasthesia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="549"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="176"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure Manager</name_or_title>
      <organization>LEO Pharma A/S</organization>
      <email>disclosure@leo-pharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

